Orange Orchid Research files open, provisional patent on SARS-CoV-2/COVID-19 treatment with the United States Patent and Trademark Office (USPTO).
LOS ANGELES, CA., September 7, 2020—Orange Orchid Research files open, provisional patent on SARS-CoV-2/COVID-19 treatment with the United States Patent and Trademark Office (USPTO). The patent details a protocol focused on alleviating early-stage, COVID-19 symptoms including (but not limited to) shortness of breath, cough, fever, chills, and muscle pain. It was developed through the utilization of the National Center for Biotechnology Information (NCBI) database and consultation with independent physicians. Each compound was determined based on its effectiveness (in regards to SARS-CoV-2 and/or other RNA-based viruses), safety and accessibility. The goal is to create a therapy based on established, medical findings using compounds which are accessible globally at low cost. The result is a seven-day treatment that provides a reduction of symptoms typically within 72 hours (based on preliminary analysis/testing) to early-stage, COVID-19 sufferers.
Principal researcher, Matthew Clark states, “The goal of the patentleft disclosure is to provide a research-based direction for further development and testing by healthcare entities around the world. We hope our research will encourage accelerated, trials of medicinal therapies related to the treatment of COVID-19.” The studies referenced were either directly applicable to COVID-19 or proven to be effective against other RNA-based viruses which mimic the replication patterns of COVID-19.
About the compounds in the patent
The two compounds referenced in the provisional patent application are N-acetylcysteine (NAC) and Cinnamomum Cassia. When combined, the compounds exhibit great promise in the clinical treatment of SARS-CoV-2. Based on studies published in the NCBI database, NAC demonstrated potential as a therapeutic agent for SARS-CoV-2 very early on [1] in part due to its ability to increase the antioxidant, glutathione [2], production in the body and potentially prevent COVID-19-associated cytokine storm and respiratory distress syndrome [3]. Dr. Steven Quay of Seattle, Washington has also used (nebulized) NAC in his openly-available protocol [4]. NAC has the added benefit of protecting the liver from oxidative stress (in addition to its antiviral properties) and works well in unison with the second compound, Cinnamomum Cassia.
Cinnamon, specifically Cinnamomum Cassia, is an anticoagulant that supplies antiviral compounds which have both been thoroughly documented as effective against COVID-19 in silico [5] and includes cinnamaldahyde which has also proven to be inhibitory against Influenza A, another RNA-based virus [6]. In addition, the seemingly rudimentary, Cinnamomum Cassia contains eugenol which has also proven to be inhibitory against both the Ebola virus [7] and Influenza A during in vitro studies [8]. Per the stated guidelines in the filing, both the NAC and Cinnamomum Cassia are administered orally, twice daily with food (with dosages of 1500mg NAC/450mg Cinnamomum Cassia respectively). It’s the combination which is critical. While both compounds are potent antivirals, they have to be combined to fight SARS-CoV-2 replication successfully. The duration of the protocol stated in the application is seven days with notable results within 72 hours. While the protocol shows great promise in its current iteration, the firm looks forward to future refinements and findings of those who freely utilize the intellectual property.
About Orange Orchid Research
Orange Orchid Research is an independently-funded firm which conducts research and prototyping services encompassing product design and intellectual property. With its first open patent filing, the company has committed itself to contributing to the global dialogue in the aim of mitigating the current global crisis. The application filing exemplifies an initiative to provide information and credible resources to healthcare professionals globally that may not otherwise have access or capability. The guidelines stated in the patent should not be utilized in lieu of medical advice nor should it be a substitute for a thorough evaluation and treatment. The contents are primarily research-based and therefore intended to advance further institutional learning and examination of the virus. Due to the patent’s open-source nature, no legal action will be taken on behalf of Orange Orchid Research against any individual, institution or company that utilizes or extrapolates the contents of the application.
Company Contact:
Matthew Clark
Principal Researcher
Orange Orchid Research
PO Box 18843
Los Angeles, CA 90018
Email: info@orangeorchidresearch.com
Website: orangeorchidresearch.com
# # #
1. Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2 [published online ahead of print, 2020 May 30]. Med Hypotheses. 2020;143:109862. doi:10.1016/j.mehy.2020.109862
2. De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19 [published online ahead of print, 2020 Aug 11]. FASEB J. 2020;10.1096/fj.202001807. doi:10.1096/fj.202001807
3. Assimakopoulos SF, Marangos M. N-acetyl-cysteine may prevent COVID-19-associated cytokine storm and acute respiratory distress syndrome [published online ahead of print, 2020 Apr 22]. Med Hypotheses. 2020;140:109778. doi:10.1016/j.mehy.2020.109778
4. Dr. Steven Quay. (2020, March 30). New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients [Press release]. Retrieved from https://www.globenewswire.com/fr/news-release/2020/03/30/2008285/0/en/New-COVID-19-HOPE-Clinical-Trial-Recommendations-Introduced-Today-May-R educe-or-Eliminate-Mechanical-Ventilation-for-Coronavirus-Patients.html
5. Prasanth DSNBK, Murahari M, Chandramohan V, Panda SP, Atmakuri LR, Guntupalli C. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2 [published online ahead of print, 2020 Jun 22]. J Biomol Struct Dyn. 2020;1-15. doi:10.1080/07391102.2020.1779129
6. Hayashi K, Imanishi N, Kashiwayama Y, et al. Inhibitory effect of cinnamaldehyde, derived from Cinnamomi cortex, on the growth of influenza A/PR/8 virus in vitro and in vivo. Antiviral Res. 2007;74(1):1-8. doi:10.1016/j.antiviral.2007.01.003
7. Lane T, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro. Pharm Res. 2019;36(7):104. Published 2019 May 17. doi:10.1007/s11095-019-2629-0
8. Fatima M, Zaidi NU, Amraiz D, Afzal F. In Vitro Antiviral Activity of Cinnamomum cassia and Its Nanoparticles Against H7N3 Influenza A Virus. J Microbiol Biotechnol. 2016;26(1):151-159. doi:10.4014/jmb.1508.08024
Note to editors:
Below are direct, online links to aforementioned references.
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261085/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436914/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195028/
4. https://www.globenewswire.com/fr/news-release/2020/03/30/2008285/0/en/New-COVID-19-HOPE-Clinical-Trial-RecommendationsIntroduced-Today-May-Reduce-or-Eliminate-Mechanical-Ventilation-for-Coronavirus-Patients.html
5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332870/
6. https://pubmed.ncbi.nlm.nih.gov/17303260/
7. https://pubmed.ncbi.nlm.nih.gov/31101988/
8. https://pubmed.ncbi.nlm.nih.gov/26403820/